IL149600A0 - Novel methods and compositions involving opioids and antagonists thereof - Google Patents

Novel methods and compositions involving opioids and antagonists thereof

Info

Publication number
IL149600A0
IL149600A0 IL14960000A IL14960000A IL149600A0 IL 149600 A0 IL149600 A0 IL 149600A0 IL 14960000 A IL14960000 A IL 14960000A IL 14960000 A IL14960000 A IL 14960000A IL 149600 A0 IL149600 A0 IL 149600A0
Authority
IL
Israel
Prior art keywords
antagonists
novel methods
compositions involving
opioids
involving opioids
Prior art date
Application number
IL14960000A
Other languages
English (en)
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of IL149600A0 publication Critical patent/IL149600A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14960000A 1999-11-29 2000-11-29 Novel methods and compositions involving opioids and antagonists thereof IL149600A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45080699A 1999-11-29 1999-11-29
PCT/US2000/042315 WO2001037785A2 (en) 1999-11-29 2000-11-29 Novel methods and compositions involving opioids and antagonists thereof

Publications (1)

Publication Number Publication Date
IL149600A0 true IL149600A0 (en) 2002-11-10

Family

ID=23789563

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14960000A IL149600A0 (en) 1999-11-29 2000-11-29 Novel methods and compositions involving opioids and antagonists thereof
IL149600A IL149600A (en) 1999-11-29 2002-05-12 Pharmaceutical compositions for use as medicaments for preventing or treating a side effect of opioids comprising an opioid in combination with a peripheral mu opioid antagonist compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149600A IL149600A (en) 1999-11-29 2002-05-12 Pharmaceutical compositions for use as medicaments for preventing or treating a side effect of opioids comprising an opioid in combination with a peripheral mu opioid antagonist compound

Country Status (13)

Country Link
EP (1) EP1244447B1 (enExample)
JP (1) JP2003528819A (enExample)
AU (1) AU784541B2 (enExample)
CA (1) CA2392362A1 (enExample)
CY (1) CY1106359T1 (enExample)
DE (1) DE60032940T2 (enExample)
DK (1) DK1244447T3 (enExample)
ES (1) ES2278647T3 (enExample)
IL (2) IL149600A0 (enExample)
MX (1) MXPA02005335A (enExample)
NZ (1) NZ518562A (enExample)
PT (1) PT1244447E (enExample)
WO (1) WO2001037785A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
DK1041987T3 (da) 1997-12-22 2006-08-21 Euro Celtique Sa Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
US6696088B2 (en) 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
ATE446751T1 (de) * 2001-06-05 2009-11-15 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
ATE419039T1 (de) 2001-07-18 2009-01-15 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
AU2002323032B2 (en) 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
PT1492505E (pt) 2002-04-05 2015-10-06 Euro Celtique Sa Preparação farmacêutica contendo oxicodona e naloxona
HUE038446T2 (hu) 2002-09-20 2018-10-29 Alpharma Pharmaceuticals Llc Szekvesztráló alegység és releváns kompozíciók és módszerek
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1844792A4 (en) * 2004-12-14 2008-05-21 Shionogi & Co THERAPEUTIC AGENT AGAINST OBSTIPATION
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EP1762569A1 (en) * 2005-09-12 2007-03-14 Alcasynn Pharmaceuticals Gmbh Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008121352A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
TWI553009B (zh) 2007-03-29 2016-10-11 普吉尼製藥公司 末梢性類鴉片受體拮抗劑及其用途
KR101519682B1 (ko) * 2007-08-09 2015-05-19 렌슬러 폴리테크닉 인스티튜트 4급 오피오이드 카르복스아미드
JP5905198B2 (ja) * 2007-10-01 2016-04-20 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
US8426594B2 (en) * 2007-11-30 2013-04-23 Purdue Pharma L.P. Benzomorphan compounds
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR20110133602A (ko) 2009-03-10 2011-12-13 유로-셀티큐 에스.에이. 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
WO2011068594A1 (en) 2009-12-04 2011-06-09 Alkermes, Inc. Morphinan derivatives for the treatment of drug overdose
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
RS65091B1 (sr) 2010-08-23 2024-02-29 Alkermes Pharma Ireland Ltd Postupci za lečenje povećanja telesne težine indukovanog antipsihoticima
EP2725908B1 (en) 2011-06-29 2017-05-31 Alkermes, Inc. Peripherally acting opioid compounds
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP2986295A4 (en) * 2013-04-17 2016-11-09 Biopharma Works PROCESS FOR PAIN TREATMENT
EP2986294A4 (en) * 2013-04-17 2016-11-16 Biopharma Works PROCESS FOR PAIN TREATMENT
EA201600033A1 (ru) 2013-07-23 2016-10-31 Еуро-Селтик С.А. Комбинация оксикодона и налоксона для лечения боли у пациентов, страдающих от боли и заболевания, приводящего к дисбиозу кишечника и/или повышению риска транслокации кишечной микрофлоры
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
PH24752A (en) * 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
JP2003528819A (ja) 2003-09-30
EP1244447A2 (en) 2002-10-02
ES2278647T3 (es) 2007-08-16
WO2001037785A9 (en) 2002-08-29
DE60032940D1 (de) 2007-02-22
AU784541B2 (en) 2006-04-27
EP1244447A4 (en) 2003-06-04
CA2392362A1 (en) 2001-05-31
CY1106359T1 (el) 2011-10-12
NZ518562A (en) 2005-04-29
DE60032940T2 (de) 2007-11-08
MXPA02005335A (es) 2003-01-28
PT1244447E (pt) 2007-02-28
DK1244447T3 (da) 2007-04-23
WO2001037785A3 (en) 2002-01-10
IL149600A (en) 2010-06-16
AU3970601A (en) 2001-06-04
EP1244447B1 (en) 2007-01-10
WO2001037785A2 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
IL149600A0 (en) Novel methods and compositions involving opioids and antagonists thereof
EP1176948A4 (en) COMPOSITIONS AND METHODS
EP1235651A4 (en) CEMENT COMPOSITION
IL190220A0 (en) Novel composition and use
HUP0203613A3 (en) Injectable buprenorphine microparticle compositions and their use
HUP0500880A2 (en) Cxcr3 antagonists and pharmaceutical compositions thereof
HUP0301201A3 (en) Methods and compositions utilizing quinazolinones
IN2001MU00967A (en) Cement additive
GB9920678D0 (en) Sanitising compositions and methods
AU6832101A (en) Composition and method
AU4163402A (en) Composition and method
SG94358A1 (en) Polishing composition and method
PL352432A1 (en) Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them
AU3958902A (en) Crf receptor antagonists and methods relating thereto
HUP0401535A3 (en) Somatostatin antagonists and their use
EG22491A (en) Rest-breaking composition and use thereof
IL153487A0 (en) Pharmaceutical compositions and methods for use
GB9922135D0 (en) Compositions and uses
HUP0301384A2 (en) Urotensin-ii agonists and antagonists
GB9927927D0 (en) Compound composition and use
AU1623801A (en) Opioid metallopeptide compositions and methods
AU5931300A (en) Ringene compositions and methods for use thereof
EP1272512A4 (en) IMMUNOKIN COMPOSITION AND METHOD
EP1311709A4 (en) METHODS AND COMPOSITIONS FOR DIRECTED MOLECULAR EVOLUTION USING MODIFICATION OF THE END OF DNA
GB9911606D0 (en) Composition and use